UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 1, 2017 (April 27, 2017)
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other Jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
235 East 42nd Street
New York, New York
(Address of principal executive offices)
10017
(Zip Code)
Registrant's telephone number, including area code:
(212) 733-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this
chapter).
Emerging growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised
financial accounting standards pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 5.07
Submission of Matters to a Vote of Security Holders
(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 27, 2017.
(b) Shareholders voted on the matters set forth below.
1. The nominees for election to the Company’s Board of Directors
were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:
Nominee
Votes For
Votes Against
Abstentions
Broker non-votes
Dennis A. Ausiello
4,152,501,049
75,514,314
13,839,358
922,977,815
Ronald E. Blaylock
4,164,933,510
62,636,919
14,294,069
922,977,815
W. Don Cornwell
4,027,032,793
200,454,995
14,382,843
922,977,815
Joseph J. Echevarria
4,175,460,147
52,326,845
14,082,675
922,977,815
Frances D. Fergusson
4,183,313,416
44,564,457
13,993,585
922,977,815
Helen H. Hobbs
4,203,418,078
25,415,701
13,037,680
922,977,815
James M. Kilts
3,428,377,699
788,781,156
24,712,604
922,977,815
Shantanu Narayen
4,187,489,160
40,233,206
14,148,394
922,977,815
Suzanne Nora Johnson
4,158,446,107
70,141,723
13,281,430
922,977,815
Ian C. Read
4,011,974,954
179,295,677
50,592,617
922,977,815
Stephen W. Sanger
4,106,265,694
97,150,063
38,455,076
922,977,815
James C. Smith
4,182,841,733
44,129,277
14,899,823
922,977,815
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2017 fiscal year
was approved based upon the following votes:
Votes for approval
5,018,058,421
Votes against
127,091,711
Abstentions
19,697,878
Broker non-votes
N/A
3. The proposal to
approve, on an advisory basis, executive compensation was approved based
upon the following votes:
Votes for approval
3,941,679,516
Votes against
269,008,927
Abstentions
31,184,241
Broker non-votes
922,977,815
4. The proposal
on the frequency of future advisory votes on executive compensation
received the following votes:
For 3 years
526,554,428
For 2 years
24,985,010
For 1 Year
3,669,882,602
Abstentions
20,344,405
Broker non-votes
922,977,815
5. The shareholder proposal
regarding The Holy Land Principles was withdrawn by the proponent and not presented at
the Annual Meeting.
6. The shareholder proposal regarding
special shareowner meetings was not approved based upon the following votes:
Votes for approval
1,941,978,794
Votes against
2,266,430,971
Abstentions
33,453,959
Broker non-votes
922,977,815
7. The shareholder
proposal regarding independent chair policy was not approved based upon the following votes:
Votes for approval
1,086,656,978
Votes against
3,122,212,329
Abstentions
32,981,454
Broker non-votes
922,977,815
(c) Not applicable.
(d) Based upon the results
set forth in item (b) (4) above, and consistent with the Board's recommendation, the Board of Directors has determined that